Avoiding Delays and Missed Opportunities in Japan: Clinical and Regulatory Strategies for Ex-Japan Biopharma
Published on: Dec. 22nd, 2025
For many ex-Japan biopharma companies, Japan represents a major market opportunity that is often delayed or deprioritized due to perceived regulatory and clinical hurdles.
As a result, products may enter Japan significantly later than in the US or EU—or fail to reach the market altogether.
This webinar will explore practical clinical and regulatory strategies to help sponsors avoid delays and missed opportunities in Japan. Topics include options for generating Japanese clinical data, early inclusion of Japan in MRCTs, recent regulatory updates affecting Japanese Phase 1 and ethnic sensitivity requirements, and best practices for PMDA consultation meetings.
Through real-world considerations and case-based insights, participants will gain a clearer understanding of how proactive planning can support timely approval and sustainable market access in Japan.
This webinar is co-organized with CoreMed.
Avoiding Delays and Missed Opportunities in Japan: Clinical and Regulatory Strategies for Ex-Japan Biopharma
As a result, products may enter Japan significantly later than in the US or EU—or fail to reach the market altogether.
This webinar will explore practical clinical and regulatory strategies to help sponsors avoid delays and missed opportunities in Japan. Topics include options for generating Japanese clinical data, early inclusion of Japan in MRCTs, recent regulatory updates affecting Japanese Phase 1 and ethnic sensitivity requirements, and best practices for PMDA consultation meetings.
Through real-world considerations and case-based insights, participants will gain a clearer understanding of how proactive planning can support timely approval and sustainable market access in Japan.
